David Staunton
Cognizant
Episode 178
Harnessing tech to improve the economics of making medicine
In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
- Why being a supplier is harder if you have not been on the client side
- An industry driven by change and the importance of digital strategy to drive business outcomes
- Why pharma companies need to be both big and fast to win
- How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks
- The future of deployable, modular factories to service population centers that provide better access to personalized medicines
- How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)
David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing and supply.
In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.
LinkedIn: (6) David Staunton | LinkedIn
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.
